Navigation Links
UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age

irable effects were somnolence, asthenia and dizziness. As adjunctive therapy in paediatric patients (4-16 years of age) with partial onset seizures the most commonly reported undesirable effects were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache. In adults and adolescents with myoclonic seizures the most common reported undesirable effects associated with Keppra® in combination with other AEDs were headache and somnolence. In adults and adolescents with primary generalized tonic-clonic seizures the most common reported undesirable effects associated with Keppra® in combination with other AEDs was fatigue. Keppra® is also indicated for intravenous administration and is available as 100 mg/mL concentrate for solution for infusion. Undesirable effects that resulted from Keppra® intravenous use are similar to those associated with Keppra® oral use. Please consult local prescribing information.

About UCB Headquartered in Brussels (Belgium), UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing more than 8400 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma.

For further enquiries, please contact

Jean-Christophe Donck Mareike Mohr Vice President, Associate Director, Investor Relations Corporate Communications and Investor Relations Tel. +32 2 559 9346 Tel. +32 2 559 9264

References [1] UCB Data on File [2] Neurological Disorders: Public Health Challenges. WHO Report 19
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/30/2015)... DUBLIN , March 30, 2015 Perrigo ... global provider of "Quality Affordable Healthcare Products®," today announced ... Pharma Invest N.V. ("Omega") in a cash and equity ... assumption of €1.3 billion in debt. Sellers are ... and co-investors of Waterland.    ...
(Date:3/30/2015)... , March 30, 2015 A team ... atomic structure of a cell-surface receptor that plays a ... research unexpectedly discloses many new structural features, which challenge ... receptors (GPCRs) and open a new door for future ... Nature on March 30, the researchers at ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/n6x9q9/marine ... "Marine Biotechnology - Global Strategic Business Report" ... and forecasts are provided for the period 2013 ... provided for these markets. Market data and analytics ... This report analyzes the worldwide markets for ...
Breaking Medicine Technology:Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7
... Feb. 22, 2011 Proacta Incorporated and ... announced the execution of a definitive agreement ... commercialization of Proacta,s PR509, a hypoxia-activated pro-drug ... (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a) (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b) ...
... ALLEGAN, Mich., Feb. 22, 2011 Perrigo Company (Nasdaq: ... has filed an Abbreviated New Drug Application for calcipotriene ... of Taclonex® Ointment. Another generic company is the first ... and Betamethasone) ointment is indicated for the topical treatment ...
Cached Medicine Technology:Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta's PR509 Compound 2Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta's PR509 Compound 3Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3
(Date:3/30/2015)... NY (PRWEB) March 31, 2015 ... / Co-Founder of Safe Hands Warm Hearts, as a ... with this prestigious distinction for leadership in home health ... the country, spanning virtually every industry and profession, the ... vibrant networking community with nearly 700,000 members and over ...
(Date:3/30/2015)... Join local United Methodists as they Rethink ... funds to provide healthcare for the 512 students at ... place on Saturday, April 18, at 9 a.m. at ... Vaughn Road in Nashville. , Raise the Roof Academy ... reliable medical care. The nearest clinic is a three-hour ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 The Consumer ... Lawyer Skills for the New Attorney” seminar for attorneys who ... event brings top trial attorneys in the Southern California area ... encounter. Doctors on Liens was on hand, ... attorneys to the doctors their clients will need to help ...
(Date:3/30/2015)... 30, 2015 GoHooper.com announces new website ... providing medical care to infants, children and adolescents and ... children. , The owner/provider Mark Hughes, MD, FAAP ... strive to provide expertise in the extensive range of ... care from health professionals who meet the medical field's ...
(Date:3/30/2015)... 2015 Wimbledon Health Partners, the leading ... and NCV testing, is proud to ... observance of National Doctor’s Day. , “Our physicians ... but on this day, we like to publicly acknowledge ... play in healing patients, promoting overall health and making ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Rachel L. Gregus, Manager / Co-Founder of Safe Hands Warm Hearts, a 2015 Professional Woman of the Year 2Health News:Hike2Heal and Rethink Church Raise Funds To Provide Healthcare for Ugandan Children with 3rd Annual Raise the Roof 5K on April 18 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 3Health News:Nashville Web Design Company Announces New Site Launch For Pediatrics Doctor 2Health News:Wimbledon Health Partners Recognizes National Doctors’ Day 2
... 2009 ADDY® Award for its multi-media drug education and prevention campaign and ... service announcements. , ... Los Angeles, Ca (PRWEB) March 19, 2009 -- ... 60 seconds in duration, brings home the stark reality of what substance ...
... replace heparin after hip- or knee-replacement surgery , ... of the experimental blood-thinning drug rivaroxaban outweigh its risks, ... Thursday. , Rivaroxaban (Xarelto) could be one of the ... hip- and knee-replacement patients. , The panel voted 15 ...
... group homes in Los Angeles County after being charged with ... or drugs seven years later, according to a new RAND ... need to improve juvenile justice rehabilitation programs, according to the ... Health . , Studies rarely track juvenile offenders for so ...
... March 19 Today, South Dakota residents have reason ... 24th state in the nation, and the first in ... virtually everyone from secondhand smoke, in both public places ... lawmakers for making great strides in protecting health and ...
... DATATRAK International, Inc. (Nasdaq: DATA ), a ... for the clinical trials industry, today announced that a ... request for continued listing on The NASDAQ Capital Market, ... 1, 2009, the Company must evidence compliance with the ...
... CDC analysis finds almost half of all cases last year ... Tuberculosis cases reached an all-time low rate in the United ... , The U.S. Centers for Disease Control and Prevention reported ... cases per 100,000 people. , However, the CDC report also ...
Cached Medicine News:Health News:Foundation for the Drug-Free World Honored with Seven ADDY Awards 2Health News:FDA Panel Backs New Anti-Clotting Drug 2Health News:Study finds most adolescents sent to group homes still involved with drugs/crime seven years later 2Health News:NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market 2Health News:NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market 3Health News:TB Still Declining in U.S., But at Slower Rate 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: